India-based vaccine maker Bharat Biotech and Spanish biopharma player Biofabri commence the clinical trials of the world's first live attenuated vaccine of Mycobacterium tuberculosis isolated from a human, MTBVAC, to evaluate its safety, immunogenicity and efficacy.